ALFA Finder| Revenue growth | FY26 core up 27% YoY (ex-real estate); headline FY26 INR 547.8cr. |
|---|---|
| Margins | EBITDA margin held at 22.3%; optimization driving expansion. |
| Demand visibility | Positive; inventory build aligned with FY27 volume planning. |
| Management confidence | High; citing recovery continues with strong all-round financials. |
Growth
FY26 Core revenue up 27%; Vitamin D3 Human +28%; D3 Animal +32%; Green Chemistry +126% YoY.
Outlook
EBITDA margin stable at 22.3%; Debt-to-equity improved to 0.27; Free cash flow tripled to INR 62cr.
Risks
Headline PAT fell 8% YoY due to FY25 real-estate base effect; inventory build for FY27 volumes.
Earnings Call filed with BSE, NSE: FERMENTA. Summary written with AI assistance from the document.
Fermenta Biotech Ltd: key numbers
- Share price
- ₹444.70
- Market cap
- ₹1,309 Cr
- Revenue (annual)
- ₹525.4 Cr
- Net profit (annual)
- ₹71.77 Cr
- P/E (TTM)
- 25.5×Sector 43.8×
- Promoter holding
- 60.12%-3.97% QoQ
- FII holding
- 1.05%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Fermenta Biotech Ltd
All →Fermenta Biotech Results Update
Fermenta Biotech reported H1FY27 consolidated revenue of Rs. 261.9 Crore, a 7% YoY decline. Profit after tax fell 52% to Rs. 18.9 Crore, impacted by lower animal nutrition pricing.
- Value
- ₹261.9 Cr
Fermenta Biotech Merger & Restructuring
Fermenta Biotech Limited's board has approved the closure of its inactive wholly-owned subsidiary, Fermenta Biotech (UK) Limited. The move aims to reorganize corporate structure and reduce compliance costs following the UK's exit from the EU.
Fermenta Biotech Q2 FY27 Results: Net Profit ₹9.4 Cr, Down 47.8% YoY
Fermenta Biotech Ltd reported revenue from operations of ₹132.7 Cr (+1.9% YoY) and net profit of ₹9.4 Cr (-47.8% YoY) for Q2 FY27.
- Key figure
- Net profit ₹9.4 Cr · -47.8% YoY
Fermenta Biotech Board Meeting Date
Fermenta Biotech schedules a board meeting on November 5, 2026 to approve unaudited quarterly and half-year results. The trading window stays closed until 48 hours after results.
Fermenta Biotech Other Announcement
Fermenta Biotech Ltd filed its quarterly shareholding pattern for the period ended September 30, 2026, in compliance with SEBI Regulation 31.
Fermenta Biotech Promoter Selling
Fermenta Biotech Limited promoter Preeti Thakkar sold 11,65,938 equity shares (3.96%) in the open market. Her shareholding decreased from 7.61% to 3.65% following the transaction.